Back to all research

PT-141 (Bremelanotide): What the Research Says

July 7, 2026

PT-141, known clinically as bremelanotide, has an unusual research history and a defined clinical record. This overview summarizes what the published research reports, strictly within a laboratory-research context.

What Is PT-141?

PT-141 (bremelanotide) is a cyclic heptapeptide and an agonist of the melanocortin receptors (reported as a selective MC1R/MC4R agonist). It is a metabolite of melanotan II, and its central-nervous-system activity was discovered incidentally during research on melanotan compounds originally studied as sunless-tanning agents.

Mechanisms Studied in Research

  • Melanocortin-receptor agonism. Bremelanotide acts centrally in the brain via melanocortin pathways; research describes effects on central signaling rather than direct vascular action.
  • Extensive clinical study. The compound has been administered to thousands of human subjects across dozens of clinical studies using various routes of administration.

Regulatory Status

The branded pharmaceutical bremelanotide (Vyleesi) received FDA approval in 2019 as an as-needed subcutaneous injection for a specific indication in premenopausal women. That approval is specific to that product and indication. Research-grade PT-141 is not the approved drug product and is supplied strictly for laboratory research use only, not for human use.

The State of the Evidence

  • Bremelanotide has a substantial clinical record tied to its approved product and indication.
  • Research-grade material is distinct from the approved medicine and is for laboratory research only.

Key Takeaways

  • PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin-receptor agonist acting centrally.
  • It was discovered incidentally from melanotan research and has an extensive clinical study history.
  • The branded drug is FDA-approved; research-grade material is not that product and is for laboratory research only.

References

  • “Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder.” PMC6819023.
  • “An effect on the subjective sexual response... by bremelanotide (PT-141), a melanocortin receptor agonist.” PMID 16839319.
  • “Bremelanotide — an overview.” ScienceDirect Topics.

Research Use, Legal Status & Handling

Material supplied for research is intended for in-vitro laboratory research use only. It is not a dietary supplement, drug, cosmetic, or food. Where an approved pharmaceutical version of a compound exists, research-grade material is not that approved product and is not intended for human or veterinary consumption, diagnosis, treatment, cure, or prevention of any condition. Researchers are solely responsible for compliance with all applicable federal, state, and local laws and regulations in their jurisdiction. Research peptides are generally stored lyophilized, protected from light and heat, with reconstitution and handling performed per standard laboratory protocols.

Disclaimer: This article is provided for educational and informational purposes only and summarizes published laboratory and, where noted, clinical research. It is not medical advice or a recommendation for any form of use. Research-grade material is intended strictly for in-vitro research use only — not for human or veterinary consumption. Always consult a qualified professional regarding health-related questions.